Medicine & Life Sciences
Survival
100%
Cholangiocarcinoma
70%
Neoplasms
65%
Progression-Free Survival
58%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
46%
Hand Hygiene
37%
Colorectal Neoplasms
34%
Confidence Intervals
31%
Hepatocellular Carcinoma
31%
Therapeutics
31%
Maximum Tolerated Dose
30%
Young Adult
30%
Drug Therapy
29%
Circulating Tumor DNA
27%
Databases
26%
Skilled Nursing Facilities
26%
Colonic Neoplasms
25%
Adenocarcinoma
24%
Clinical Trials
22%
Immunotherapy
22%
Mesothelioma
22%
Leukemia
20%
Biomarkers
18%
Pancreatic Neoplasms
18%
Nivolumab
18%
Multicenter Studies
18%
Acute Myeloid Leukemia
18%
Disease-Free Survival
17%
Subacute Care
17%
gossypol acetic acid
16%
pegaspargase
16%
oblimersen
16%
vatalanib
16%
tipifarnib
16%
cediranib
16%
navitoclax
16%
Krukenberg Tumor
15%
lenvatinib
15%
AZD 6244
15%
entinostat
15%
HhAntag691
15%
Cell Transplantation
15%
Pediatrics
15%
Gossypol
14%
Farnesyltranstransferase
14%
Cyclotrons
14%
Nursing Homes
14%
Receptor, Fibroblast Growth Factor, Type 2
14%
Vascular Endothelial Growth Factor A
14%
Histone Deacetylase 1
14%
Mathematics
Toxicity
48%
Dose Finding
43%
Design
31%
Dose
24%
Efficacy
19%
Phase I Trial
15%
Bayesian Design
13%
Cycle
13%
Biomarkers
12%
Oncology
10%
End point
10%
Clinical Trials
10%
Binary
10%
Clustering
8%
Tumor
6%
Interval
6%
Subgroup
6%
Sample Size
5%
Continual Reassessment Method
5%
Target
5%